Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

[1]  N. Howlett,et al.  Application of a Biphasic Mathematical Model of Cancer Cell Drug Response for Formulating Potent and Synergistic Targeted Drug Combinations to Triple Negative Breast Cancer Cells , 2020, Cancers.

[2]  H. Ford,et al.  Cellular Plasticity in Breast Cancer Progression and Therapy , 2020, Frontiers in Molecular Biosciences.

[3]  Z. Shao,et al.  Molecular subtypes and precision treatment of triple-negative breast cancer , 2020, Annals of translational medicine.

[4]  D. Rauh,et al.  Spotlight on AKT: Current Therapeutic Challenges. , 2020, ACS medicinal chemistry letters.

[5]  S. Mok,et al.  Pathogenesis and Clinical Management of Uterine Serous Carcinoma , 2020, Cancers.

[6]  Yeon-Hee Park,et al.  AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. , 2018 .

[7]  Prabhjot S. Mundi,et al.  Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial , 2018, Clinical and Translational Oncology.

[8]  G. Mills,et al.  A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors , 2017, Clinical Cancer Research.

[9]  M. Espié,et al.  Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2017, The Lancet. Oncology.

[10]  Zachary L. Skidmore,et al.  A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer , 2017, Clinical Cancer Research.

[11]  B. Taylor,et al.  AKT Inhibition in Solid Tumors With AKT1 Mutations. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Philip,et al.  Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial , 2017, JAMA oncology.

[13]  K. Do,et al.  A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Michael L. Wang,et al.  Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma , 2014, British journal of haematology.

[15]  P. Munster,et al.  A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies , 2015, Clinical Cancer Research.

[16]  Funda Meric-Bernstam,et al.  Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Berry,et al.  Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. , 2015 .

[18]  G. Mills,et al.  SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. , 2015, Journal of the National Cancer Institute.

[19]  Yuan Qi,et al.  Clinical actionability enhanced through deep targeted sequencing of solid tumors. , 2015, Clinical chemistry.

[20]  Martin O. Leach,et al.  Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers , 2014, Clinical Cancer Research.

[21]  G. Mills,et al.  Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer , 2014, Clinical Cancer Research.

[22]  S. Chandarlapaty,et al.  A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors , 2013, Breast Cancer Research.

[23]  G. Mills,et al.  Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer , 2012, Clinical Cancer Research.

[24]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Mills,et al.  Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.

[26]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[27]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[28]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[29]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[30]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[31]  Teri A. Crosby,et al.  How to Detect and Handle Outliers , 1993 .